News

NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment

NeuroOne stock rallies after FDA clears its OneRF system, a minimally invasive solution targeting severe facial pain, scheduled to launch in late 2025.
GlobalData on MSN3d

NeuroOne’s nerve ablation system secures FDA clearance

NeuroOne Medical Technologies has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for its OneRF ...
MassDevice4d

NeuroOne wins FDA nod for nerve ablation system that treats facial pain

Trigeminal nerve ablation, a minimally invasive procedure, uses RF energy to destroy abnormal tissue and relieve severe, ...

InnovationRx: Phil Knight’s $2 Billion Cancer Gift

In this week’s edition of InnovationRx, we look at Phil Knight’s big cancer gift, Medallion’s credentialing clearinghouse, a ...
TipRanks on MSN4d

NeuroOne Medical receives FDA 510k clearance for OneRF

Technologies has received U.S. Food and Drug Administration, FDA, clearance to market its OneRF Trigeminal Nerve Ablation ...
TipRanks on MSN4d

NeuroOne Gains FDA Clearance for Nerve Ablation System

NeuroOne Medical Technologies ( ($NMTC) ) has provided an announcement. On August 18, 2025, NeuroOne Medical Technologies Corporation announced it ...
BioWorld3d

Neuroone's Onerf wins FDA clearance for trigeminal nerve ablation

Neuroone Medical Technologies Corp. expanded into treatment of chronic pain with a new U.S. FDA clearance for use of its Onerf system to treat trigeminal nerve pain. The system uses radiofrequency ...